Spotrate News

Pharma

Biotechnology, drug development, clinical trials, and healthcare innovation.

Featured Company Videos

▶
Overview | VisionWave Holdings, Inc.VisionWave Holdings, Inc.NASDAQ:VWAV
▶
Company Overview | Oncolytics Biotech® Inc.Oncolytics Biotech® Inc.NASDAQ:ONCY
▶
Overview | GT Biopharma, Inc.GT Biopharma, Inc.NASDAQ:GTBP
▶
Overview | Avai Bio Inc.Avai Bio Inc.NASDAQ:AVAI
▶
Overview | Quantum Secure Encryption Corp.Quantum Secure Encryption Corp.CSE:QSE
▶
Overview | Goldhaven Resources Corp.Goldhaven Resources Corp.CSE:GOH
▶
Overview | Aleen Inc.Aleen Inc.CSE:ALEN-U

Bloomberg|News

▶
Xi Hosts 'Groundbreaking' Trilateral With Trump, Putin
▶
Trump Calls Xi a 'Friend' as Leaders Hold Talks in China
▶
Anthropic Raises $107.3 Billion in Watershed AI Debut
▶
Trump Set to Meet With Xi and Putin in China
▶
Fed Minutes Leave Door Open to Larger December Rate Hike
▶
CITI CEO Jane Fraser | Bloomberg Newsmakers Interview
▶
Anthropic Could Launch the Biggest IPO Ever
▶
Anthropic IPO Is Fairly Priced, Says Dharmesh Thakker
▶
Xi Welcomes Trump at Shenzhen Airport
▶
AI Trade Is ‘Alive and Well,’ Says Edward Yardeni
▶
Xi Greets Trump Ahead of Bilateral and Trilateral Talks
▶
Anthropic Is Said to Guide IPO Price to Top of Range

CNBC|News

▶
Jim Cramer talks strength beneath the surface in the economy
▶
Some of the data center stocks are buying huge amounts of stock in the open markets, says Jim Cramer
▶
Brinker International CEO Kevin Hochman sits down with Jim Cramer
▶
Novo Nordisk CEO Mike Doustdar sits down with Jim Cramer
▶
Sysco CEO Kevin Hourican goes one-on-one with Jim Cramer
▶
There are no guarantees when it comes to thematic investing, says Jim Cramer
▶
Memory is the new gold, says Arista Networks CEO Jayshree Ullal
▶
ServiceNow CEO: We have a kill switch if AI agents go rogue
▶
I like data centers so much that I wish I lived in one, says Jim Cramer
▶
If you own too much tech, now is the time to use caution, says Jim Cramer
▶
I'm too worried about these trends to say IBM's now safe to buy, says Jim Cramer
▶
Boring stocks win when oil goes higher because of Iran war, says Jim Cramer

Market Summary

1

Global Pharma Market: ~$1.5T+ Annual Revenue

2

FDA Approvals Drive Valuation Inflection Points

3

Late-Stage Assets Command Premium Multiples

4

Biotech M&A Remains a Core Growth Engine

Industry Insights

1

Biotech and pharmaceutical companies operate within a highly regulated, research-driven environment where clinical and regulatory milestones define valuation cycles.

2

FDA approvals and late-stage trial outcomes serve as primary catalysts, often resulting in rapid market cap expansion or contraction.

3

Large-cap pharmaceutical companies rely on external innovation through partnerships and acquisitions to sustain long-term growth pipelines.

4

Patent expiry cycles create recurring revenue pressure, driving reinvestment into next-generation therapies and pipeline development.

5

Oncology, rare diseases, and precision medicine continue to dominate R&D focus due to strong pricing power and unmet medical demand.

6

Institutional capital is typically concentrated in companies with advanced clinical assets and clearly defined regulatory pathways.

Industry Leaders

Eli Lilly

LLY

Global pharmaceutical leader in obesity, diabetes, and oncology.

Novo Nordisk

NVO

Leader in diabetes care and GLP-1 therapies.

Johnson & Johnson

JNJ

Diversified healthcare and pharmaceutical giant.

Merck & Co.

MRK

Oncology and vaccine powerhouse (Keytruda).

AbbVie

ABBV

Immunology and oncology-focused biopharma company.

Amgen

AMGN

Biotech leader in biologics and biosimilars.

Gilead Sciences

GILD

Antiviral and oncology-focused biotech.

Regeneron Pharmaceuticals

REGN

Innovative biotech in immunology and eye care.

Vertex Pharmaceuticals

VRTX

Leader in cystic fibrosis and gene-based therapies.

Moderna

MRNA

mRNA platform biotechnology company.

Sector Stocks

Replimune Group

REPL

Oncolytic immunotherapy development.

ORIC Pharmaceuticals

ORIC

Targeted cancer therapies.

Anixa Biosciences

ANIX

Cancer immunotherapy and vaccines.

ImmunityBio

IBRX

Cell-based immunotherapy platform.

Iovance Biotherapeutics

IOVA

Tumor-infiltrating lymphocyte therapies.

Precigen

PGEN

Gene and cell therapy platform.

Exelixis

EXEL

Cancer-focused biotech therapeutics.

Incyte

INCY

Oncology and inflammation treatments.

BridgeBio Pharma

BBIO

Genetic disease therapeutics.

Krystal Biotech

KRYS

Gene therapy innovation.

Kymera Therapeutics

KYMR

Targeted protein degradation platform.

Moderna

MRNA

mRNA-based therapeutics and vaccines.

Regeneron Pharmaceuticals

REGN

Biologic drug development leader.

Vertex Pharmaceuticals

VRTX

Genetic disease therapies.

BioMarin Pharmaceutical

BMRN

Rare disease treatments.

Alnylam Pharmaceuticals

ALNY

RNA interference therapeutics.

Trading Platforms

Emilee Gagliardi: Starting a New Chapter at Merck as a Regional Medical Scientific Director in Breast Oncology

Emilee Gagliardi: Starting a New Chapter at Merck as a Regional Medical Scientific Director in Breast Oncology

Emilee Gagliardi: Starting a New Chapter at Merck as a Regional Medical Scientific Director in Breast Oncology...

11/19/2026
Josep Tabernero GAGO Award

Josep Tabernero GAGO Award

Josep Tabernero receives the Gago Award on European Science Policy for his contribution to advancing European ...

11/19/2026
Biosimilars in Bone Metastases: First Real-World Data on Switching

Biosimilars in Bone Metastases: First Real-World Data on Switching

In patients with solid tumours, bone is one of the most frequent sites of metastatic spread. Skeletal involvem...

11/19/2026
Biocon Strengthens Oncology Portfolio with Pertuzumab Biosimilar for HER2-Positive Breast Cancer

Biocon Strengthens Oncology Portfolio with Pertuzumab Biosimilar for HER2-Positive Breast Cancer

Biocon Limited has strengthened its oncology portfolio with its pertuzumab biosimilar, intended for use in tre...

11/19/2026
Phase II survival results reported for lenvatinib and pembrolizumab in advanced thymic tumors

Phase II survival results reported for lenvatinib and pembrolizumab in advanced thymic tumors

Final results from the Phase II PECATI clinical trial demonstrate encouraging long-term survival outcomes for ...

11/19/2026
Beta Drugs Collaborates With IMGSA Groupe SPA For Oncology Manufacturing In Algeria

Beta Drugs Collaborates With IMGSA Groupe SPA For Oncology Manufacturing In Algeria

Beta Drugs Limited is partnering with IMGSA Groupe SPA for local manufacturing of specialized oncology formula...

11/19/2026
Engineered Nanocarriers Shield Therapeutic Probiotics Against Gastrointestinal Degradation in Oncology Trials

Engineered Nanocarriers Shield Therapeutic Probiotics Against Gastrointestinal Degradation in Oncology Trials

A comprehensive scientific review shows engineered nanocarriers preserve over 90 percent of therapeutic probio...

11/19/2026
Local oncologist weighs in on ifosfamide, chemotherapy drug shortage

Local oncologist weighs in on ifosfamide, chemotherapy drug shortage

PORTSMOUTH, Va. (WAVY) — Hearing the words, “You have cancer,” can devastate one’s heart and soul. Now imagine...

11/19/2026
Kyntra Bio stock pivots after Q3 results, ends oncology programs

Kyntra Bio stock pivots after Q3 results, ends oncology programs

Kyntra Bio stock faces a pipeline reset after third-quarter results and the end of two oncology prog...

11/19/2026
MAF Test Launches in the US Through NeoGenomics, Challenging Menopause as the Bisphosphonate Gatekeeper

MAF Test Launches in the US Through NeoGenomics, Challenging Menopause as the Bisphosphonate Gatekeeper

MAF Test Launches in the US Through NeoGenomics, Challenging Menopause as the Bisphosphonate Gatekeeper / Adju...

11/19/2026
Jia (Jenny) Liu: Global Registrational Readiness Must Be Designed In, Not Retrofitted

Jia (Jenny) Liu: Global Registrational Readiness Must Be Designed In, Not Retrofitted

Jia (Jenny) Liu: Global Registrational Readiness Must Be Designed In, Not Retrofitted / cancer, FDA, ivonescim...

11/18/2026
Gilberto Lopes on Ivonescimab and the FDA Decision: When Is Progression-Free Survival Enough?

Gilberto Lopes on Ivonescimab and the FDA Decision: When Is Progression-Free Survival Enough?

Gilberto Lopes on Ivonescimab and the FDA Decision: When Is Progression-Free Survival Enough? / cancer, FDA, H...

11/18/2026
Pyxis Oncology’s ADC Shows Potential for Treating Head and Neck Cancer

Pyxis Oncology’s ADC Shows Potential for Treating Head and Neck Cancer

Pyxis Oncology’s antibody-drug conjugate MICVO shows promising early stage efficacy and manageable safety in a...

11/18/2026
Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium

Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium

Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed O...

11/18/2026
Imène Hadji: Where is Cancer Immunotherapy Heading?

Imène Hadji: Where is Cancer Immunotherapy Heading?

Imène Hadji: Where is Cancer Immunotherapy Heading? / cancer, colorectal cancer, CS2009, ESMO, esmo 2026, ESMO...

11/18/2026
Sergio Cifuentes-Canaval: ctDNA Surveillance in High-Risk ER+/HER2- Early Breast Cancer

Sergio Cifuentes-Canaval: ctDNA Surveillance in High-Risk ER+/HER2- Early Breast Cancer

Sergio Cifuentes-Canaval: ctDNA Surveillance in High-Risk ER+/HER2- Early Breast Cancer / AFC Okines, Annals o...

11/18/2026
Palliative Radiation: Small Treatment, Big Difference

Palliative Radiation: Small Treatment, Big Difference

Palliative Radiation: Small Treatment, Big Difference / cancer, India Hub, OncoDaily, Oncology, palliative rad...

11/18/2026
OLOL Cancer Institute names new oncology chief

OLOL Cancer Institute names new oncology chief

FMOL Health | Our Lady of the Lake Cancer Institute has appointed Dr. Nakhle Saba as its inaugural chief of me...

11/18/2026
Servier Shares Extended Follow-Up Data on VORANIGO in IDH-Mutant Glioma

Servier Shares Extended Follow-Up Data on VORANIGO in IDH-Mutant Glioma

Servier Shares Extended Follow-Up Data on VORANIGO in IDH-Mutant Glioma / glioma, IDH-mutant glioma, Neuro-Onc...

11/18/2026
Giuseppe Procopio: New Evidence and Unanswered Questions in Adjuvant Kidney Cancer Treatment

Giuseppe Procopio: New Evidence and Unanswered Questions in Adjuvant Kidney Cancer Treatment

Giuseppe Procopio: New Evidence and Unanswered Questions in Adjuvant Kidney Cancer Treatment / Adjuvant pembro...

11/18/2026
Spatial Transcriptomics of TKI Response in Metastatic Clear Cell Renal Cell Carcinoma

Spatial Transcriptomics of TKI Response in Metastatic Clear Cell Renal Cell Carcinoma

Spatial Transcriptomics of TKI Response in Metastatic Clear Cell Renal Cell Carcinoma / cancer, cancer care, C...

11/18/2026
Can AI Fix Clinical Trial Access in Oncology? Arturo Loaiza-Bonilla, MD, Built the Answer With the Data to Back It

Can AI Fix Clinical Trial Access in Oncology? Arturo Loaiza-Bonilla, MD, Built the Answer With the Data to Back It

<div><img src="https://cdn.sanity.io/images/0vv8moc6/onclive/796d06689c57c655e004f731522bfc041d07a462-1280x720...

11/18/2026
Onward Therapeutics Raises $28 Million To Advance Oncology Pipeline

Onward Therapeutics Raises $28 Million To Advance Oncology Pipeline

Onward Therapeutics has raised NT$900 million, or approximately $28 million, in Series B financing to support ...

11/18/2026
Longitudinal Community Training Helps Prepare Oncology Fellows for Their Future Careers

Longitudinal Community Training Helps Prepare Oncology Fellows for Their Future Careers

Deepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and ...

11/18/2026
UK: Icon Oncology Group acquires Nova Healthcare

UK: Icon Oncology Group acquires Nova Healthcare

Icon Oncology Group acquires Nova Healthcare...

11/18/2026